Corpus Intelligence EBITDA Bridge — NEW YORK PRESBYTERIAN HOSPITAL 2026-04-26 04:00 UTC
EBITDA Bridge — NEW YORK PRESBYTERIAN HOSPITAL
CCN 330101 | NY | 2850 beds | Current EBITDA $-103.9M → Pro Forma $462.3M (+$566.2M)
🛡️ Public data only — no PHI permitted on this instance.
$7.69B
Net Revenue HCRIS
$-103.9M
Current EBITDA COMPUTED
+$566.2M
RCM EBITDA Uplift
$462.3M
Pro Forma EBITDA
+736bps
Margin Improvement
$295.0M
WC Released (1x)

Bridge Realization Estimate

ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)

52%
Realization (D)
$566.2M
Modeled Uplift
$295.5M
Risk-Adjusted
-$270.7M
Execution Discount
Bed CountHigher Bed Count reduces execution likelihood
Occupancy RateHigher Occupancy Rate increases execution likeliho
Revenue per BedHigher Revenue per Bed increases execution likelih
Commercial Payer %Commercial Payer % has minimal effect on execution
Scale (Log Beds)Scale (Log Beds) has minimal effect on execution

Expected realization: 52% of modeled bridge. Strengths: Occupancy Rate, Revenue per Bed. Risks: Bed Count. Risk-adjusted uplift: $295.5M (vs $566.2M modeled).

EBITDA Bridge — 7 RCM Levers

Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).

Net Collection Rate
Revenue | 18mo ramp
$161.5M
+210bp
Cost to Collect
Cost Savings | 12mo ramp
$153.8M
+200bp
Denial Rate Reduction
Revenue | 12mo ramp
$152.3M
+198bp
A/R Days Reduction
Cash Accel | 9mo ramp
$93.6M
+122bp
Clean Claim Rate
Cost Savings | 6mo ramp
$4.9M
+6bp
Total EBITDA Impact$566.2M

Lever Detail

Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.

LeverCurrentTargetRevenueCostEBITDAWCRamp
Net Collection Rate93.5% DEFAULT97.0% BENCHMARK$161.5M$0$161.5M$018mo
Cost to Collect4.5% DEFAULT2.5% BENCHMARK$0$153.8M$153.8M$012mo
Denial Rate Reduction12.0% DEFAULT6.5% BENCHMARK$148.1M$4.2M$152.3M$012mo
A/R Days Reduction52.00 DEFAULT38.00 BENCHMARK$23.6M$70.0M$93.6M$295.0M9mo
Clean Claim Rate88.0% DEFAULT96.0% BENCHMARK$0$4.9M$4.9M$06mo
CDI / Case Mix Index135.0% DEFAULT142.0% BENCHMARK$0$0$0$018mo

Implementation Timing Curve

Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.

LeverM0M3M6M9M12M18M24M36
Net Collection Rate$0$26.9M$53.8M$80.8M$107.7M$161.5M$161.5M$161.5M
Cost to Collect$0$38.5M$76.9M$115.4M$153.8M$153.8M$153.8M$153.8M
Denial Rate Reduction$0$38.1M$76.1M$114.2M$152.3M$152.3M$152.3M$152.3M
A/R Days Reduction$0$31.2M$62.4M$93.6M$93.6M$93.6M$93.6M$93.6M
Clean Claim Rate$0$2.5M$4.9M$4.9M$4.9M$4.9M$4.9M$4.9M
Cumulative$0$137.1M$274.2M$408.9M$512.3M$566.2M$566.2M$566.2M

Returns Sensitivity (IRR / MOIC)

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $566.2M is added at exit.

Entry \ Exit9.0x10.0x11.0x11.5x12.0x
8.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
9.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
10.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
11.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x
12.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x-100% / 0.0x

Covenant Headroom (at 10x Entry, 6.5x Max Leverage)

99.0x
Entry Leverage
-1.9x
Pro Forma Leverage
8.4x
Headroom (turns)
129%
EBITDA Cushion

Pro forma EBITDA can decline 129% before the 6.5x covenant trips. RCM uplift reduces leverage from 99.0x to -1.9x, adding 100.9 turns of cushion.

5-Year Value Creation Waterfall

EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).

Base EBITDARCM UpliftTotalMargin
Entry$-103.9M$-103.9M-1.4%
Year 1$-107.0M+$377.4M$270.5M3.5%
Year 2$-110.2M+$566.2M$456.0M5.9%
Year 3$-113.5M+$566.2M$452.7M5.9%
Year 4$-116.9M+$566.2M$449.3M5.8%
Year 5$-120.4M+$566.2M$445.8M5.8%
$-1.04B
Entry EV (10x)
$4.90B
Exit EV (11x)
$5.94B
Value Created
$445.8M
Exit EBITDA
$-165.4M
Organic Growth
$5.66B
RCM Value Creation
$445.8M
Multiple Expansion

Achievement Sensitivity

What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.

Lever50%75%100%120%
Net Collection Rate$80.8M$121.1M$161.5M$193.8M
Cost to Collect$76.9M$115.4M$153.8M$184.6M
Denial Rate Reductio$76.1M$114.2M$152.3M$182.8M
A/R Days Reduction$46.8M$70.2M$93.6M$112.3M
Clean Claim Rate$2.5M$3.7M$4.9M$5.9M
Total$283.1M$424.6M$566.2M$679.4M

Peer Context — Where This Hospital Sits

Key metrics vs 9 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.

MetricHospitalP25P50P75Percentile
Op Margin-1.4%-20.2%-1.4%2.5%
P44
Net-to-Gross27.4%13.3%19.7%25.0%
P89
Occupancy86.7%63.2%80.0%83.6%
P89
Rev/Bed$2.7M$879K$1.6M$2.0M
P78
Exp/Bed$2.7M$1.1M$1.7M$1.9M
P78

Bridge Methodology

Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.

Data: HCRIS FY2022 | 6,123 hospitalsSources: HCRISML